Patient-Focused Drug Development for Nontuberculous Mycobacterial Lung Infections; Public Meeting, 46026-46027 [2015-18919]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 80, Number 148 (Monday, August 3, 2015)]
[Notices]
[Pages 46026-46027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18919]



[[Page 46026]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0967]


Patient-Focused Drug Development for Nontuberculous Mycobacterial 
Lung Infections; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
a public meeting and an opportunity for public comment on Patient-
Focused Drug Development for nontuberculous mycobacterial (NTM) lung 
infections. Patient-Focused Drug Development is part of FDA's 
performance commitments made as part of the fifth authorization of the 
Prescription Drug User Fee Act (PDUFA V). The public meeting is 
intended to allow FDA to obtain patient perspectives on the impact of 
NTM lung infections on daily life and patient views on treatment 
approaches. FDA is also interested in discussing issues related to 
scientific challenges in developing drugs to treat NTM lung infections. 
In the afternoon, FDA will hold a workshop and provide information for 
and gain perspective from patients and patient advocacy organizations, 
health care providers, academic experts, and industry on various 
aspects of clinical development of drug products intended to treat NTM 
lung infections. The input from this public meeting will help in 
developing topics for further discussion.

DATES: The public meeting will be held on October 15, 2015, from 9 a.m. 
to 5 p.m. Please register for the meeting by October 7, 2015. 
Registration from those individuals interested in presenting comments 
as part of the panel discussions should be received by September 28, 
2015. See the SUPPLEMENTARY INFORMATION section for instructions on how 
to register for the meeting. Submit electronic or written comments to 
the public docket by December 15, 2015.

ADDRESSES: The meeting and workshop will be held at the FDA White Oak 
Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great 
Room (Rm. 1503), Silver Spring, MD 20993-0002. Participants must enter 
through Building 1 and undergo security screening. For more information 
on parking and security procedures, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    Submit electronic comments to www.regulations.gov. Submit written 
comments to the Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All 
comments should be identified with the docket number found in brackets 
in the heading of this document.
    FDA will post the agenda approximately 5 days before the meeting at 
https://www.fda.gov/Drugs/NewsEvents/ucm453877.htm.

FOR FURTHER INFORMATION CONTACT: Graham Thompson, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993, 301-796-
5003, FAX: 301-847-8443, graham.thompson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background on Patient-Focused Drug Development

    FDA has selected NTM lung infections as the focus of a public 
meeting under Patient-Focused Drug Development, an initiative that 
involves obtaining a better understanding of patient perspectives on 
the severity of a disease and the available therapies for these 
conditions. Patient-Focused Drug Development is being conducted to 
fulfill FDA performance commitments that are part of the 
reauthorization of PDUFA under Title I of the Food and Drug 
Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144). 
The full set of performance commitments is available at https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf.
    FDA committed to obtain the patient perspective on 20 disease areas 
during the course of PDUFA V. For each disease area, the Agency will 
conduct a public meeting to discuss the disease and its impact on 
patients' daily lives, the types of treatment benefit that matter most 
to patients, and patients' perspectives on the adequacy of the 
available therapies. These meetings will include participation of FDA 
review divisions, the relevant patient communities, and other 
interested stakeholders.
    On July 2, 2015, FDA published a notice (80 FR 38216) in the 
Federal Register announcing the disease areas for meetings in fiscal 
years 2016-2017, the final 2 years of the PDUFA V time frame. The 
Agency used several criteria outlined in that notice to develop the 
list of disease areas. FDA obtained public comment on the Agency's 
proposed criteria and potential disease areas through a public docket. 
In selecting the set of disease areas, FDA carefully considered the 
public comments received and the perspectives of review divisions at 
FDA. More information, including the list of disease areas and a 
general schedule of meetings, is posted at https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm326192.htm.

II. Purpose and Scope of the Meeting

    The purpose of this Patient-Focused Drug Development meeting is to 
obtain input on the symptoms and other impacts of NTM lung infections 
that matter most to patients, as well as perspectives on current 
approaches to treating this condition. NTM infections can affect all 
organs in the body; however, NTM infections primarily affect the lungs, 
especially in patients with underlying lung disease. Common causes of 
NTM lung infections include Mycobacterium avium-intracellulare and 
Mycobacterium abscessus. Symptoms of NTM lung infections include 
chronic cough, shortness of breath, blood in sputum, fever, fatigue, 
loss of appetite, night sweats, and weight loss. There are no FDA-
approved therapies for NTM lung infections. Treatment requires a 
combination of drugs given for prolonged duration. The antibacterial 
drugs used can cause severe side effects that make treatment of this 
condition difficult. FDA is committed to working with all stakeholders 
to develop safe and effective therapies for affected individuals.
    The questions that will be asked of patients and patient 
stakeholders at the meeting are listed in this section, organized by 
topic. For each topic, a brief initial patient panel discussion will 
begin the dialogue. This will be followed by a facilitated discussion 
inviting comments from other patient and patient stakeholder 
participants. In addition to input generated through this public 
meeting, FDA is interested in receiving patient input addressing these 
questions through written comments, which can be submitted to the 
public docket (see ADDRESSES). When submitting comments, if you are 
commenting on behalf of a child please indicate that you are doing so 
and answer the following questions as much as possible from the 
patient's perspective.

[[Page 46027]]

Topic 1: Disease Symptoms and Daily Impacts That Matter Most to 
Patients

    1. Of all the symptoms that you experience because of your 
condition, which 1-3 symptoms have the most significant impact on your 
life? (Examples may include cough, increased sputum production, 
shortness of breath, difficulty breathing, chest pain)
    2. Are there specific activities that are important to you but that 
you cannot do at all or as fully as you would like because of your 
condition? (Examples of activities may include sleeping through the 
night, daily hygiene, driving, walking/running, exercising, etc.)
     How do your symptoms and their negative impacts affect 
your daily life on the best days? On the worst days? (Examples may 
include limitations on the ability to undertake physically strenuous 
activities, restrictions on the ability to travel, inability to sleep, 
lack of appetite, fatigue, etc.)
    3. How has your condition and its symptoms changed over time?
     Do your symptoms come and go? If so, do you know of 
anything that makes your symptoms better? Worse?
    4. What worries you most about your condition?

Topic 2: Patients' Perspectives on Current Approaches To Treating NTM 
Lung Infections

    1. What are you currently doing to help treat your condition or its 
symptoms? (Examples may include prescription medicines, over-the-
counter products, nebulizers, and other therapies including non-drug 
therapies)
     What specific symptoms do your treatments address?
     How has your treatment regimen changed over time, and why?
    2. How well does your current treatment regimen treat the most 
significant symptoms of your disease?
     How well do these treatments stop or slow the progression 
of your disease?
     How well do these therapies improve your ability to do 
specific activities that are important to you in your daily life?
     How well have these treatments worked for you as your 
condition has changed over time?
    3. What are the most significant downsides to your current 
treatments, and how do they affect your daily life? (Examples of 
downsides may include bothersome side effects, need for multiple 
medications, need for injections, going to the hospital for treatment, 
etc.)
    4. Assuming there is no complete cure for your condition, what 
specific things would you look for in an ideal treatment for your 
condition?
    In the afternoon, discussion will be related to scientific topics, 
with the goal of understanding issues that may affect the development 
of drugs for the treatment of NTM lung infections and identifying 
topics for future discussion. Discussion topics for the afternoon will 
include the following: Epidemiology and natural history of NTM lung 
infections, current treatment considerations, clinical trial designs, 
and clinical trial endpoints.

III. Attendance and Registration

    If you wish to attend this meeting, visit https://ntmpfdd.eventbrite.com. Please register by October 7, 2015. If you are 
unable to attend the meeting in person, you can register to view a live 
Webcast of the meeting. You will be asked to indicate in your 
registration if you plan to attend in person or via the Webcast. 
Seating will be limited, so early registration is recommended. 
Registration is free and will be on a first-come, first-served basis. 
However, FDA may limit the number of participants from each 
organization based on space limitations. Registrants will receive 
confirmation once they have been accepted. Onsite registration on the 
day of the meeting will be based on space availability.
    If you need special accommodations because of a disability, please 
contact Graham Thompson at least 7 days before the meeting.

IV. Comments

    Patients who are interested in presenting comments as part of the 
initial panel discussions will be asked to indicate in their 
registration which topic(s) they wish to address. These patients also 
must send to PatientFocused@fda.hhs.gov a brief summary of responses to 
the topic questions by September 28, 2015. Panelists will be notified 
of their selection approximately 7 days before the public meeting. We 
will try to accommodate all patients and patient stakeholders who wish 
to speak, either through the panel discussion or audience 
participation; however, the duration of comments may be limited by time 
constraints.
    FDA will hold an open public comment period to give the public an 
opportunity to comment. Registration for open public comment will occur 
at the registration desk on the day of the meeting and workshop on a 
first-come, first-served basis.
    Regardless of attendance at the public meeting, you can submit 
electronic or written responses to the questions pertaining to topics 1 
and 2 to the Division of Dockets Management (see ADDRESSES) by December 
15, 2015. It is only necessary to send one set of comments. Identify 
comments with the docket number found in brackets in the heading of 
this document. Received comments may be seen in the Division of Dockets 
Management between 9 a.m. and 4 p.m., Monday through Friday, and will 
be posted to the docket at https://www.regulations.gov.

V. Transcripts

    As soon as a transcript is available, FDA will post it at https://www.fda.gov/Drugs/NewsEvents/ucm453877.htm.

    Dated: July 28, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-18919 Filed 7-31-15; 8:45 am]
BILLING CODE 4164-01-P